These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 21903279)
21. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Rasmussen SG; Choi HJ; Fung JJ; Pardon E; Casarosa P; Chae PS; Devree BT; Rosenbaum DM; Thian FS; Kobilka TS; Schnapp A; Konetzki I; Sunahara RK; Gellman SH; Pautsch A; Steyaert J; Weis WI; Kobilka BK Nature; 2011 Jan; 469(7329):175-80. PubMed ID: 21228869 [TBL] [Abstract][Full Text] [Related]
22. Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors. Lakkaraju SK; Yu W; Raman EP; Hershfeld AV; Fang L; Deshpande DA; MacKerell AD J Chem Inf Model; 2015 Mar; 55(3):700-8. PubMed ID: 25692383 [TBL] [Abstract][Full Text] [Related]
23. Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models. Vilar S; Ferino G; Phatak SS; Berk B; Cavasotto CN; Costanzi S J Mol Graph Model; 2011 Feb; 29(5):614-23. PubMed ID: 21146435 [TBL] [Abstract][Full Text] [Related]
24. GPCR crystal structures: Medicinal chemistry in the pocket. Shonberg J; Kling RC; Gmeiner P; Löber S Bioorg Med Chem; 2015 Jul; 23(14):3880-906. PubMed ID: 25638496 [TBL] [Abstract][Full Text] [Related]
25. Detection of G protein-selective G protein-coupled receptor (GPCR) conformations in live cells. Malik RU; Ritt M; DeVree BT; Neubig RR; Sunahara RK; Sivaramakrishnan S J Biol Chem; 2013 Jun; 288(24):17167-78. PubMed ID: 23629648 [TBL] [Abstract][Full Text] [Related]
27. Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. Katritch V; Reynolds KA; Cherezov V; Hanson MA; Roth CB; Yeager M; Abagyan R J Mol Recognit; 2009; 22(4):307-18. PubMed ID: 19353579 [TBL] [Abstract][Full Text] [Related]
28. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents. Saleh N; Ibrahim P; Clark T Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446 [TBL] [Abstract][Full Text] [Related]
30. A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity. Sanchez-Soto M; Verma RK; Willette BKA; Gonye EC; Moore AM; Moritz AE; Boateng CA; Yano H; Free RB; Shi L; Sibley DR Sci Signal; 2020 Feb; 13(617):. PubMed ID: 32019899 [TBL] [Abstract][Full Text] [Related]
31. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Staus DP; Strachan RT; Manglik A; Pani B; Kahsai AW; Kim TH; Wingler LM; Ahn S; Chatterjee A; Masoudi A; Kruse AC; Pardon E; Steyaert J; Weis WI; Prosser RS; Kobilka BK; Costa T; Lefkowitz RJ Nature; 2016 Jul; 535(7612):448-52. PubMed ID: 27409812 [TBL] [Abstract][Full Text] [Related]